GATA-1 and the ets factor PU.1 have been reported to functionally antagonize one another in the regulation of erythroid versus myeloid gene transcription and development. The CCAAT enhancer binding protein ⑀ (C/EBP⑀) is expressed as multiple isoforms and has been shown to be essential to myeloid (granulocyte) terminal differentiation. We have defined a novel synergistic, as opposed to antagonistic, combinatorial interaction between GATA-1 and PU.1, and a unique repressor role for certain C/EBP⑀ isoforms in the transcriptional regulation of a model eosinophil granulocyte gene, the major basic protein (MBP). The eosinophil-specific P2 promoter of the MBP gene contains GATA-1, C/EBP, and PU.1 consensus sites that bind these factors in nuclear extracts of the eosinophil myelocyte cell line, AML14.3D10. The promoter is transactivated by GATA-1 alone but is synergistically transactivated by low levels of PU.1 in the context of optimal levels of GATA-1. The C/EBP⑀ 27 isoform strongly represses GATA-1 activity and completely blocks GATA-1/PU.1 synergy. In vitro mutational analyses of the MBP-P2 promoter showed that both the GATA-1/PU.1 synergy, and repressor activity of C/EBP⑀ 27 are mediated via protein-protein interactions through the C/EBP and/or GATA-binding sites but not the PU.1 sites. Co-immunoprecipitations using lysates of AML14.3D10 eosinophils show that both C/EBP⑀ 32/30 and ⑀ 27 physically interact in vivo with PU.1 and GATA-1, demonstrating functional interactions among these factors in eosinophil progenitors. Our findings identify novel combinatorial protein-protein interactions for GATA-1, PU
Hematopoietic development is regulated in part by the combinatorial actions of transcription factors that coordinate temporal and lineage-specific patterns of gene expression. The transcription factors GATA-1, PU.1, and members of the CCAAT enhancer binding protein (C/EBP) 1 
family (C/EBP␣
and C/EBP⑀ in particular) are essential for the commitment and/or terminal differentiation of myeloid progenitors to the eosinophil lineage (1) (2) (3) (4) (5) (6) (7) (8) (9) . A direct interaction and functional antagonism between GATA-1 and PU.1 have been reported recently by several groups (10 -12) . PU.1 has also been shown to directly or indirectly interact with multiple transcription factors including C/EBP␣, C/EBP␦ (NF-IL6␤, CRP3), c-Jun, c-Myb, AML1, and NF-B (13) (14) (15) (16) (17) . GATA-1, a zinc finger family member, has been shown to be essential for virtually all aspects of erythroid and megakaryocyte gene transcription and lineage development (18 -20) . We have shown that eosinophil-committed promyelocytic cell lines express GATA-1-3 mRNA in an inducible fashion, and peripheral blood eosinophils of mixed developmental maturity isolated from patients with the hypereosinophilic syndrome also express GATA-1 mRNA (21) . Studies in the avian system using myb-ets-transformed myeloid progenitors have suggested that an intermediate level of GATA-1 expression in the context of C/EBP␤ and PU.1 is critical for eosinophil lineage-specific gene expression and differentiation (1, 2, 7, 12, 22) . As well, GATA-1 expression is slowly down-regulated during eosinophilopoiesis in the avian system (3, 7) . However, the GATA-1 null mutation in the mouse has not been evaluated for defects in eosinophil development.
PU.1, an ets family member, is selectively expressed in B lymphocytes, granulocytes, and monocytes and is required for the development of these hematopoietic lineages (23) (24) (25) (26) (27) (28) . During the proliferation and differentiation of multipotential lymphoid-myeloid progenitors, PU.1 is expressed at all stages of granulocyte development, both during the early onset of expression of the GM-CSF and G-CSF receptors in myeloid progenitors (27) (28) (29) (30) , and during the more terminal differentiation steps that include expression of the CD11b, CD18, and Fc␥RI receptors (31) (32) (33) (34) (35) . PU.1 expression increases gradually through the myelocytic stages of hematopoietic development and then remains relatively constant through terminal differentiation (26, 36) . Importantly, graded expression levels of PU.1 in the mouse have been shown to specify distinct cell lineage fates in hematopoietic development, with low levels of PU.1 specifying lymphocytic and high levels specifying monocytic differentiation (37) . Moreover, disruption of the PU.1 gene affects multiple hematopoietic lineages, including defects in granulocyte terminal differentiation, resulting in the absence of functionally mature neutrophils (24, 25, 28, 38) and eosinophils 2 (39) . Thus, PU.1 is a critical regulator of hematopoietic gene transcription that possesses multiple and varied roles at different stages of both lymphoid and myeloid development.
The CCAAT/enhancer-binding proteins (C/EBPs), members of leucine zipper transcription factor family, include six members to date, of which four (C/EBP␣, -␤, -␦, and -⑀) are expressed in the myeloid lineages and play key roles in hematopoiesis and/or functional maturation of these cells, and two (C/EBP␥ and -) lack transactivation domains and act as dominant negative repressors of transcription (40, 41) . C/EBP␣ is expressed in a variety of tissues with the highest expression levels in adipose and liver (42, 43) . C/EBP␣ plays a critical role in the terminal differentiation of hepatocytes, lipid storage, and early granulocyte development (14, 15, 42, 44 -48) . The null mutation of C/EBP␣ in mice results in profound abnormalities in glucose metabolism and granulocyte (both neutrophil and eosinophil) development, including impaired G-CSF receptor signaling (15, 16, 49 -52) . C/EBP␤, originally identified as a mediator of IL-6 signaling (53, 54) , is critical for lipid storage, Th1 immune responses, and macrophage function (55, 56) , but targeted disruption of the C/EBP␤ gene had no effect on hematopoietic development.
C/EBP⑀, the most recently identified C/EBP family member, is expressed almost exclusively in the myeloid lineages and is mostly restricted to the later stages of differentiation from the promyelocyte to mature granulocyte (57) . Disruption of the C/EBP⑀ gene blocks the terminal differentiation of granulocytes, including impaired production of eosinophils (4) and decreased, but not loss, expression of a number of eosinophil secondary (specific) granule protein genes (see Fig. 10 ). 3 A frameshift mutation in the C/EBP⑀ gene has been implicated recently (58, 59) as the primary defect specifying neutrophilspecific granule deficiency. Four isoforms of C/EBP⑀ (32, 30, 27 , and 14 kDa), generated by alternative promoter usage, mRNA splicing, and different translation start sites have been identified (60 -62) . Structural and functional analyses have shown that full-length C/EBP⑀ 32 (32-kDa isoform) contains both transcriptional activation and repression domains (61) (62) (63) . The C/EBP⑀ 27 isoform contains DNA binding, dimerization, transactivation, and possible repression domains, whereas C/EBP⑀ 14 is the only isoform that lacks a transactivation domain. Essentially nothing is known about the differential expression of the C/EBP⑀ 27 and ⑀ 14 isoforms during hematopoietic development nor their activities or specific roles in myeloid gene expression. Although C/EBP family proteins generally bind DNA as either homo-or heterodimers (64) , dimer formation was not detected for C/EBP⑀ 32 expressed recombinantly in either bacteria or mammalian cells (65) .
Functional and physical interactions between C/EBP␤ and GATA-1 were first identified in vitro through our studies of the transcriptional regulation of the gene encoding the human eosinophil granule major basic protein (MBP) (9) , in which we demonstrated synergy between these factors in the transactivation of the MBP promoter. Regulation of an eosinophil-specific gene (EOS47) by the combinatorial actions of C/EBP␤, ets-1, and GATA-1 has also been reported for the avian system (2, 3) . In the present study, we have further characterized the eosinophil-specific MBP-P2 promoter, identifying novel combinatorial interactions among GATA-1, PU.1, and the C/EBP⑀ 27 isoform that result in either synergistic activation or transcriptional repression. Human MBP, one of the principal mediators of inflammation and tissue damage in eosinophil-associated allergic responses, is expressed by eosinophils (66) , and to a lesser extent by basophils (67) , and a proform of MBP is elaborated by placental trophoblasts during gestation (68, 69) . Two different MBP transcripts are regulated by alternative splicing from two distinct promoters (P1 and P2) located 34 kb apart (70) . Eosinophils and basophils transcribe principally from the P2 promoter, whereas the P1 promoter predominates in placental cells (8, 70) .
We identified previously a major functional region for the MBP-P2 promoter between bp Ϫ117 and Ϫ67 (8, 9) . In the present studies, a more extensive consensus binding site analysis showed that the bp Ϫ117 to ϩ1 region of the promoter contains not one but two adjacent GATA-binding sites, two C/EBP sites, and two previously unidentified PU.1 sites, suggesting that the combinatorial activities of all three of these factors are involved in MBP gene transcription. Because PU.1 has been reported to antagonize GATA-1-mediated erythroid gene expression and development (10 -12) , and we have shown that GATA-1 is a key regulator of the MBP gene, we utilized the MBP-P2 promoter as a model to characterize further the combinatorial interactions and roles of GATA-1, PU.1, and C/EBP⑀ in the eosinophil lineage. Consensus sites in the functional region of the MBP-P2 promoter were evaluated for their ability to bind GATA, PU.1, or C/EBP family members using nuclear extracts from the MBP-expressing eosinophil myelocyte cell line, AML14.3D10, and mature peripheral blood eosinophils. The functional relevance of these binding sites and transcription factor interactions were evaluated using mutagenesis, transactivation analyses in CV-1 cells, and transient transfection analyses in AML14.3D10 eosinophils. Co-immunoprecipitation (co-IP) experiments were performed to confirm the in vivo physical interactions of GATA-1, PU.1, and the various C/EBP⑀ isoforms in eosinophil cell lines and mature peripheral blood eosinophils.
Our results show that GATA-1, PU.1, and the various C/EBP⑀ isoforms are differentially expressed, and physically and functionally interact during human eosinophil development to activate and then repress eosinophil gene transcription. In contrast to the functional antagonism reported for PU.1 and GATA-1 for activation of the M-CSFR promoter and various erythroid genes, we show that these factors cooperate synergistically in the activation of the eosinophil MBP-P2 promoter. Importantly, we demonstrate that PU.1 expression levels relative to GATA-1 determine whether the GATA-1/PU.1 interaction leads to synergy for GATA-1-regulated eosinophil target genes such as MBP. Moreover, we identify a novel role for the C/EBP⑀ 27 isoform as a repressor of GATA-1-mediated transactivation and GATA-1/PU.1 synergy. Finally, co-IP analyses demonstrate for the first time that the C/EBP⑀ 32/30 and C/EBP⑀ 27 isoforms physically interact with both PU.1 and GATA-1 in vivo, in eosinophils. Our findings demonstrate key combinatorial interactions of GATA-1, PU.1, and C/EBP⑀ isoforms that may mediate either synergy or antagonism (repression) of granulocyte (eosinophil) gene transcription during myeloid development and terminal differentiation.
EXPERIMENTAL PROCEDURES
Primary Cells and Cell Lines-Human blood eosinophils were isolated from a unit (475 ml) of blood obtained from normal, non-allergic, healthy donors. The use of normal human subjects as blood donors was in full compliance with all federal guidelines and was approved by the University of Illinois Institutional Review Board. Eosinophil isolation and purification were performed as described previously (71) using a Miltenyi Biotec SuperMacs immunomagnetic sorting kit and apparatus according to manufacturer's specifications. Eosinophil preparations of Ͼ99% purity were routinely obtained and utilized for these studies. The human AML14.3D10 cell line is a fully differentiated eosinophil mye-locyte line that contains eosinophil secondary (specific) granules and displays many characteristics of mature peripheral blood eosinophils. These include expression of the secondary granule cationic proteins major basic protein, eosinophil peroxidase, eosinophil-derived neurotoxin, and eosinophil cationic protein (72, 73) . AML14.3D10 cells can be induced to express chemokine receptors (e.g. for eotaxins) (74) and express GM-CSF which drives their proliferation, differentiation, and survival in culture (75) . The AML14 parental cell line is a human myeloid leukemia-derived myeloblast committed to the eosinophil lineage. AML14 and AML14.3D10 cells were maintained in RPMI 1640 supplemented with 8% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 5 ϫ 10 Ϫ5 M ␤-mercaptoethanol without any antibiotics. Cells were passaged every 3-4 days and maintained at a concentration between 3 ϫ 10 5 and 1 ϫ 10 6 cells/ml. CV-1 cells were maintained by passage twice weekly in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, penicillin (10 units/ml), and streptomycin (10 g/ml) and were used for transfection at 60 -70% confluence.
Whole Cell Lysates and Nuclear Extract-AML14.3D10 eosinophils were lysed in a lysis buffer containing 0.5-1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 200 M sodium orthovanadate, 50 mM Hepes, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, 1.5 mM magnesium chloride, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml aprotinin (76), supplemented with protease inhibitor mixture tablets (Roche Molecular Biochemicals) for 1 h at 4°C. Whole cell lysates were collected by centrifugation at 14,000 ϫ g for 20 min at 4°C to remove cell debris, and lysates were stored at Ϫ80°C. Nuclear extracts were prepared by the method of Dignam et al. (77) with minor modifications, including the use of protease inhibitor mixture tablets (Roche Molecular Biochemicals) and the addition of phenylmethylsulfonyl fluoride (0.5 mM) and diisopropylfluorophosphate (1 mM) to the resuspension and lysis buffers (78, 79) . The protein concentration of nuclear or whole cell extracts was determined by the BCA method (Pierce), and extracts were aliquoted and stored at Ϫ80°C.
DNA Constructs and Mutagenesis-The bp Ϫ117MBP-P2-pXP2 luciferase reporter gene construct was described in detail previously (8, 9) . Mutagenesis PCR was performed to create mutations in the PU.1, GATA-1, or C/EBP consensus sites that block transcription factor binding using the QuickChange TM PCR kit (Stratagene, CA). Dr. Daniel Tenen kindly provided the M-CSFR promoter construct (M-CSFRpXP2). The expression vector PU.1-pECE contains the mouse cDNA for PU.1 and was a gift from Dr. R. Maki (23) . The GATA-1-pXM expression vector contains the murine GATA-1 cDNA and was kindly provided by Dr. L. Zon (80, 81) . Both C/EBP␣ and -␤, in the pMSV expression vector, were kindly provided by Dr. A. Friedman, and the various C/EBP⑀ isoforms in the pcDNA3 expression vector (pc⑀32, pc⑀27, and pc⑀14) were kindly provided by Dr. K. Xanthopoulos. All DNA constructs used in transfection and transactivation experiments were prepared by alkaline lysis maxi-preparation followed by CsCl 2 purification as described previously (79, 82) .
Western Blotting and Co-immunoprecipitations-Western blotting was performed as described previously (71, 76) using either whole cell lysates or nuclear extracts from blood eosinophils, AML14.3D10 eosinophil myelocytes, and undifferentiated AML14 parental cells. HL-60 and K562 cell lines were used as positive controls as appropriate to the transcription factors being analyzed. Twenty g of each extract was separated by SDS-PAGE and electroblotted onto Immobilon-P transfer membranes (Millipore, MA) following standard procedures. Antibodies against GATA-1 (M-20), PU.1 (T-21 and N-19), and C/EBP⑀ (C-20) and negative control antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All antibodies were non-cross-reactive with other members of their respective transcription factor families. In particular, the antibodies to PU.1 do not recognize other ets family proteins. The blots were analyzed using an enhanced chemiluminescence kit (Pierce) following the manufacturer's recommended procedure. Immunoprecipitation (IP) and co-IP were carried out using total cell lysates. Antibodies used for IP and co-IP were the same as used for Western blotting. IP and co-IP were performed essentially as described previously (71, 76) . Briefly, the whole cell lysate from 2 to 4 ϫ 10 7 AML14.3D10 cells was precleared with 1-2 g of normal rabbit, goat, or rat affinity-purified IgG antibodies plus protein A-or G-Sepharose (Amersham Biosciences) with rotation at 4°C for 2.5 h. Antibodies were added to the precleared whole cell lysates for 2 h of rotation at 4°C. Non-immune purified rabbit, rat, and goat immunoglobulin (Santa Cruz Biotechnology) were utilized as negative controls. Protein A-or protein G-Sepharose was added to the lysates for another 2 h at 4°C. Immunoprecipitates were washed 4 times with 0.1% Triton X-100 lysis buffer and analyzed by Western blotting.
Electrophoretic Mobility Shift Assays (EMSA)-Oligonucleotides containing the GATA, PU.1, and C/EBP consensus sites in the MBP-P2 promoter were synthesized and purified by Integrated DNA Technologies, Inc. (Coralville, Iowa). Double-stranded probes were end-labeled with [␥-32 P]ATP (PerkinElmer Life Sciences) and purified on 15% polyacrylamide gels as described previously (79) . Probe sequences were as follows: dual GATA sites (5Ј-GTCCTTATCAGCCTTGCTATCTCCCT-3Ј), PU.1 site 1 (5Ј-CCCTGGGGGAAGTTCCTCCAAGGCCT-3Ј), PU.1 site 2 (5Ј-AAGTCTTTGTGAGAGGAAGCAAAGAA-3Ј), C/EBP site (5Ј-GAAGTGATGAAATGGTCC-3Ј), C/EBP and GATA-1 sites (5Ј-GAAG-TGATGAAATGGTCCTTATCAGCCT-3Ј). EMSAs were performed as described previously (71) . The same antibodies used for Western blotting and co-IP were also used for supershift analyses but were supershift grade (Santa Cruz Biotechnology). The antibodies to PU.1 (T-21 and N-19) were specifically chosen because they are non-cross-reactive with other ets family member proteins.
Transactivation and Transient Transfection Assays-Transactivation experiments were performed using the DMRIE-C reagent (Invitrogen) for transfections according to the manufacturer's protocol. CV-1 cells (60 -80% confluent in 6-well plates) were transfected with 0.5 g of the MBP-P2-pXP2 wild-type or mutant promoter constructs in the presence or absence of expression vectors for PU.1 (0.001-0.1 g), GATA-1 (0.2 g), and/or C/EBP␣ and -␤, or ⑀ 32 , ⑀ 27 , or ⑀ 14 isoforms (0.2 g). Because GATA-1 may be an activator at low levels or a repressor at high levels of expression as reported for the avian Eos-47 eosinophil promoter (2, 7) , the amount of the GATA-1 expression vector added (0.2 g) to co-transactivations with PU.1 was first optimized by doseresponse titration in order to provide maximum transactivation of the MBP-P2-pXP2 promoter construct. The empty vectors corresponding to each of the transcription factors were used to normalize the total DNA content of each reaction. Transfection efficiency was normalized by the addition of 0.2 g of the pRL-CMV (Renilla luciferase) control reporter. Promoter activities were determined using the Dual-luciferase Reporter Assay System (Promega) 48 h after transfection. Luciferase activities were measured as relative light units using an EG & G Berthold Lumat LB 1507 Luminometer as described previously (71) . Results are reported as the mean Ϯ S.D. (fold induction over control) for at least three independent transactivation experiments. Transient transfections of the AML14 parental and AML14.3D10 eosinophil cell lines were performed by electroporation as described previously (71, 79) . Briefly, 10 g of each DNA construct and 1.5 ϫ 10 7 cells were used in each reaction. Promoter activities (relative light units) were measured 6 h after electroporation, and transfection efficiency was normalized using the pRL-CMV vector as above in the dual luciferase assay. Results are reported as the mean Ϯ S.D. (fold induction over control) for at least three independent experiments.
Semi-quantitative Reverse Transcriptase-PCR-Total RNA was prepared from fetal liver or bone marrow cells of mice with targeted disruptions of the C/EBP␣ (50, 52) and C/EBP⑀ (4) genes using standard purification methods as described previously (4, 83) . C/EBP⑀ null mice were first stimulated for 4.5 or 24 h with 4% thioglycolate broth by intraperitoneal injection prior to harvesting the bone marrow as described previously (4). The RNA was electrophoresed on 1% formaldehyde agarose gels, and 18 S and 28 S bands were visualized by ethidium bromide staining to assess the quality. Three g of total RNA was reverse-transcribed with random hexadeoxynucleotide primers using a First-strand cDNA Synthesis kit (Amersham Biosciences) according to the manufacturer's protocol. Calculations were based on the assumption that 100% of the RNA was reverse-transcribed to cDNA. The PCR primer pairs for cDNA amplification of murine MBP were forward 5Ј-CCAAGGAAGAGGACACAACAAGTC-3Ј and reverse 5Ј-TTGAC-CCTGGTTGATTCCCC-3Ј; GAPDH forward 5Ј-CCATGGAGAAGGCT-GGGG-3Ј and reverse 5Ј-CAAAGTTGTCATGGATGACC-3Ј. BLAST search analysis of these primers indicated they were specific for the genes of interest. The signal from amplification of the GAPDH cDNA (mRNA) was used first as a control to normalize the amount of cDNA input for subsequent PCR amplification of each sample. The PCR mix contained 10 -50 ng of cDNA, 10 pmol of each primer, 200 M dNTPs, 0.3 l of 10 mCi/ml [␣- 32 P]dCTP (PerkinElmer Life Sciences), 0.5 l of 100 mg/l of bovine serum albumin, 10ϫ PCR buffer, and 0.5 ml (2.5 units) of Taq DNA polymerase from Roche Molecular Biochemicals. The total reaction volume was 50 l. The number of PCR cycles determined to yield a linear, quantitative signal for MBP and GAPDH were 30 and 21, respectively. Each reaction cycle consisted of 50 s at 94°C for DNA denaturation, 45 s at the annealing temperature for the primer pair (55°C and 53°C for mMBP1 and GAPDH, respectively), and 45 s at 72°C for extension. Following PCR amplification, 5 l of PCR buffer was analyzed by electrophoresis on 6% native polyacrylamide gels.
RESULTS

PU.1, GATA-1, and C/EBP⑀ Isoforms Are Differentially Expressed in Eosinophilic Cell Lines and Mature Blood Eosinophils and Bind to the Their Consensus Sites in the Functional
Region of the MBP-P2 Promoter-We identified a number of additional GATA-1 and C/EBP consensus sites, as well as two PU.1 consensus sites not characterized previously in the MBP-P2 promoter, using subsequence homology searches of the bp Ϫ117 to ϩ1 functionally active region (Fig. 1) . This is the region for which we had shown previously the most 5Ј GATA-1 and C/EBP sites to be necessary for MBP promoter activity in eosinophilic cell lines using deletional and mutagenesis analyses (8, 9) . We first determined the expression patterns for GATA-1, PU.1, and C/EBP⑀ in AML14 eosinophilic cell lines and mature peripheral blood eosinophils by Western blotting (Fig. 2) , and their binding activity for the multiple consensus sites was identified in the MBP-P2 promoter by gel shifts (Fig.  3) . Expression levels for GATA-1, PU.1, and the various C/EBP⑀ isoforms was compared for AML14 parental myeloblasts, AML14.3D10 eosinophil myelocytes, and peripheral blood eosinophils from normal donors, covering the range of differentiation stages from undifferentiated progenitors to terminally differentiated mature eosinophils. GATA-1 was well expressed both for undifferentiated AML14 parental cells and differentiated AML14.3D10 eosinophilic myelocytes ( Fig. 2A , lanes 1 and 2) but was undetectable in normal peripheral blood eosinophils ( Fig. 2A, lane 3 ) from two different donors (2nd donor not shown). K562 cells, which express abundant endogenous GATA-1 protein, were used as the positive control ( Fig.  2A, lane 4) . This finding suggests that GATA-1 expression is significantly down-regulated during eosinophil terminal differentiation, supporting prior results in the avian system (2, 7). PU.1 was also expressed by both AML14 parental myeloblasts and AML14.3D10 eosinophil myelocytes with AML14 Ͻ AML14.3D10 (Fig. 2B , lanes 1 and 2) but not detectable in mature blood eosinophils and K562 cells (Fig. 2B, lanes 3 and  4) . However, much longer exposure times revealed weak expression in both blood eosinophils and K562 cells (not shown). This finding indicates a significant reduction in PU.1 expression as eosinophils terminally differentiate. All four isoforms of C/EBP⑀ including C/EBP⑀ 32/30 , C/EBP⑀ 27 , and C/EBP⑀ 14 were well expressed in AML14.3D10 eosinophilic myelocytes (Fig.  2C , lane 2), comparable with HL-60 promyelocytes (lane 4), but expression was lower in the AML14 myeloblast line (Fig. 2C , lane 1). Importantly, only the C/EBP⑀ 14 isoform is abundantly expressed in terminally differentiated blood eosinophils (Fig.  2C, lane 3) , a finding confirmed using two different blood donors (Fig. 2C, lanes 5 and 6) . The high level expression of C/EBP⑀ 14 in blood eosinophils was initially detected as a broad smear on Western blots using equal protein loading for all nuclear extracts (Fig. 2C, lane 3) . We therefore reduced protein loading by a factor of 10 to show the C/EBP⑀ 14 signal as a single 14-kDa band in the blood eosinophils from two different normal subjects (Fig. 2C, lanes 5 and 6) . Further reductions in protein loading eliminated all isoforms of C/EBP⑀ expressed by AML14.3D10 cells but still showed a sharp single band for the C/EBP⑀ 14 isoform expressed by authentic blood eosinophils (not shown), indicating very high level expression of C/EBP⑀ 14 in the mature eosinophil. These findings demonstrate that GATA-1, PU.1, and C/EBP⑀ are all well expressed in the AML14.3D10 eosinophil myelocyte cell line, which is therefore an ideal model for functional studies of the roles of GATA-1, PU.1, and C/EBP⑀ isoforms in vivo and in vitro. The differential expression of the C/EBP⑀ isoforms in developing eosinophil progenitors versus the mature, terminally differentiated cell may reflect their specific roles as activators and then repressors of eosinophil gene expression during granulocyte development (see below and Fig. 11 ).
The bp Ϫ117 to ϩ1 functional region of the MBP-P2 promoter possesses two consensus sites each for GATA-1, PU.1, and the C/EBPs (Fig. 1) . To assess their ability to bind these factors, we performed gel and antibody supershift analyses using nuclear extracts from the AML14.3D10 eosinophil myelocyte cell line and [␥-
32 P]ATP-end-labeled oligonucleotides containing the GATA-1, PU.1, and C/EBP consensus sites of interest (Fig. 3) . GATA-1 binds to the two tandem GATA sites in the promoter (Fig. 3A) . Two specific protein-DNA-binding complexes formed with the AML14.3D10 nuclear extract using the dual GATA site probe (Fig. 3A, lane 2) . Complex formation was completely inhibited by the addition of a 100-fold molar excess of the unlabeled dual GATA site oligonucleotide (lane 3), partially inhibited by oligonucleotides containing only the first or second GATA site (lanes 4 and 5) but not inhibited by oligonucleotides containing a dual GATA site mutation (lane 6). The GATA-binding complexes were completely supershifted by an antibody to GATA-1 (lane 7) but not by antibodies to PU.1 or 27 the various C/EBPs (lanes 8 -11 ). These results demonstrate that GATA-1 binds to both GATA consensus sites comprising the dual GATA-1 site of the MBP-P2 promoter, with maximum binding to the dual site as compared with the single sites (data not shown).
GATA-1 and PU.1 Synergy and Its Repression by C/EBP⑀
For the PU.1 consensus sites, two major protein-DNA complexes formed with nuclear extract from AML14.3D10 cells using the second PU.1 consensus site as a probe (Fig. 3B, lane  2) . Formation of these complexes was completely inhibited by the addition of a 100-fold molar excess of the unlabeled probe (lane 3) but only the higher mobility complex (PU.1) was removed by competition with both the first (not shown) and second PU.1 sites (lane 4), indicating the specificity of this complex. This PU.1 complex was selectively blocked by the addition of two different antibodies to PU.1 (lanes 8 and 9) but not by antibodies against GATA-1 or the C/EBPs (lanes 10 -13) . These results demonstrate that both PU.1 consensus sites in the MBP promoter have the capacity to bind PU.1 expressed by   FIG. 2. Differential expression of PU.1, GATA-1, and C/EBP⑀ isoforms in eosinophil progenitor and myelocytic cell lines compared with mature peripheral blood eosinophils. Western blot analysis of the levels of PU.1, GATA-1, and C/EBP⑀ isoforms using nuclear extracts from AML14 (eosinophil myeloblast) and AML4.3D10 (eosinophil myelocyte) cell lines and mature peripheral blood eosinophils (Ͼ99% purity) from two different normal subjects. Western blots were probed with GATA-1 antibody (A), PU.1 antibody (B), and C/EBP⑀ antibody (C). K562 nuclear extract was used as a positive control for GATA-1 and PU.1. HL-60 nuclear extract was used as a positive control for C/EBP⑀ expression. FIG. 3 . PU.1, GATA-1, and C/EBP⑀ in AML14.3D10 eosinophil nuclear extracts bind to their consensus sites in the MBP-P2 promoter. A, GATA-1 binds to the dual GATA sites in the MBP-P2 promoter. The gel shift assay used the dual GATA consensus site in the MBP-P2 promoter as probe. Two specific complexes formed with nuclear extract from AML14.3D10 eosinophilic myelocytes (lane 2). These complexes were completely inhibited by the addition of unlabeled self-competitors (lane 3) and partially inhibited by an oligonucleotide containing only a single GATA site (lanes 4 and 5) but not by a dual GATA site mutation (lane 6). The protein-DNA complexes were completely supershifted by the addition of antibody to GATA-1 (lane 7) but not by antibodies to PU.1 or the C/EBPs (␣, ␤, and ⑀) (lanes 8 -11) . B, PU.1 binds to both PU.1 consensus sites in the MBP-P2 promoter. The gel shift was performed using the second PU.1 consensus site of the MBP-P2 promoter as probe. Two protein-DNA complexes formed with nuclear extract of AML14.3D10 cells as indicated by the arrows (lane 2). Although both complexes were completely inhibited by the addition of unlabeled probe (the 2nd PU.1 site) (lane 3), only the higher mobility complex (labeled PU.1) was specifically eliminated by the addition of competitor containing the first PU.1 site (lane 4) but not by other transcription factor-binding sites (lanes 5-7) . This PU.1 complex was also eliminated by the addition of two different antibodies to PU.1 (lanes 8 and 9) but not by antibodies to GATA-1, C/EBP␣, -␤, or -⑀ (lanes 10 -13) . C, C/EBP␤ and C/EBP⑀ both bind to the first (most 5Ј) C/EBP consensus site in the MBP-P2 promoter. The gel shift was performed using both C/EBP consensus sites of the MBP-P2 promoter as probes. However, no binding was detected using the 2nd C/EBP site. Two specific complexes formed with the first C/EBP consensus site using nuclear extract of AML14.3D10 eosinophils (lane 1, bands ␤ and ␤⑀). Complex formation was completely inhibited by the addition of unlabeled competitors including self or the C/EBP consensus site of the M-CSFR promoter (lanes 2 and 4, respectively) but not by a C/EBP binding site mutation (lane 3). Antibody to C/EBP⑀ completely removed and supershifted complex ⑀ and partially removed complex ␤⑀ (lane 8). The addition of antibody to C/EBP␤ partially removed complex ␤⑀ (lane 6). Supershifted bands (S ⑀ and S ␤ ) were detected by addition of both C/EBP⑀ and C/EBP␤ antibodies (lanes 6 and 8) but not by antibodies to C/EBP␣ and C/EBP␦ (lanes 5 and 7) .
AML14.3D10 eosinophils. For the C/EBP consensus sites in the MBP promoter, both C/EBP⑀ and C/EBP␤ in AML14.3D10 eosinophil nuclear extracts formed specific protein-DNA complexes with the first C/EBP site (Fig. 3C) . Complex formation was completely inhibited by the addition of a 100-fold molar excess of an unlabeled C/EBP consensus site oligonucleotide matching the MBP-P2 or M-CSFR promoters (lanes 2 and 4) but not by an oligonucleotide containing a C/EBP site mutation (lane 3). One of the DNA-binding complexes was completely supershifted by the addition of antibody to C/EBP⑀ (lane 8). A second, higher mobility binding complex was partially removed by the addition of antibody to C/EBP␤ or C/EBP⑀. No C/EBP␣ or C/EBP␦ complexes were detected using AML14.3D10 eosinophil nuclear extracts (lanes 5 and 7) , whereas in equivalent gel shifts using AML14 parental cell nuclear extracts, only C/EBP␣ complexes could be identified by antibody supershift (not shown). The second C/EBP consensus site in the promoter did not form any complexes, nor did it inhibit complex formation with the first C/EBP site (not shown). These results indicate that C/EBP␤ and C/EBP⑀ homodimers, as well as C/EBP␤-C/EBP⑀ heterodimers, present in AML14.3D10 eosinophil nuclear extracts bind to the first C/EBP site in the MBP-P2 promoter; this is the C/EBP site we previously showed to be functionally transactivated by C/EBP␤ (9) and in the present study by C/EBP␣ as well (see Fig. 9A ).
Synergy Versus Antagonism between GATA-1 and PU.1-As noted above, a functional antagonism between GATA-1 and PU.1 has been reported for the transcriptional regulation of myeloid genes such as the M-CSFR (11), for which the promoter possesses a functional PU.1 site but no GATA sites, and GATA-1 antagonizes PU.1 transactivating activity. Because the MBP-P2 promoter possesses both GATA-1-and PU.1-binding sites, and the MBP-P2 promoter is strongly transactivated by GATA-1, we sought to determine whether PU.1 would similarly antagonize GATA-1 activity in our system. Transactivation experiments were performed in CV-1 cells by transfection of the bp Ϫ117MBP-P2 luciferase reporter construct with GATA-1 and/or PU.1 expression vectors (Fig. 4A) . Because GATA-1 has been shown previously (2, 7) to function as an activator at low concentrations and repressor at high concentrations for an avian eosinophil promoter EOS47, we first performed dose-response titrations of the GATA-1 expression vector to determine the optimal concentration for maximal GATA-1 transactivation of the MBP-P2-pXP2 reporter construct (data not shown); this optimal amount was used for all subsequent co-transactivation assays. A PU.1-regulated M-CSFR promoter construct, used previously to demonstrate GATA-1 antagonism of PU.1 transactivation (11), was also transfected into CV-1 cells along with the same GATA-1 and/or PU.1 expression vectors in these experiments for comparison (Fig. 4B) . Contrary to the anticipated PU.1 antagonism of GATA-1, our results clearly show that MBP-P2 promoter activity was induced ϳ20-fold by GATA-1 alone and ϳ60-fold by GATA-1 plus PU.1, with PU.1 alone being essentially inactive (Fig. 4A) .
These results demonstrate a significant synergy of PU.1 for the GATA-1-mediated transactivation of the MBP-P2 promoter, in contrast to the antagonism of GATA-1 for the PU.1-mediated transactivation of the M-CSFR promoter as reported previously (11) and confirmed in the current "control" experiments (Fig. 4B) . The findings provide evidence for important promoter-specific and possible lineage-specific differences in the combinatorial outcome of GATA-1/PU.1 interactions in myeloid gene regulation in general and eosinophil gene regulation in particular during eosinophil development. To further evaluate the synergistic activities of GATA-1 and PU.1 for transactivation of the MBP-P2 promoter, we performed dose-response analyses using different amounts of PU.1 expression vector at an optimal concentration of the GATA-1 expression vector. The M-CSFR promoter was again evaluated in these experiments as a control for a PU.1-regulated gene that is antagonized by GATA-1. Surprisingly, we found that the synergistic transactivation of the MBP-P2 promoter by GATA-1 and PU.1 occurred in the presence of low levels of PU.1 but was completely abrogated by high levels of PU.1 (Fig. 4C) . In contrast, PU.1-mediated transactivation of the M-CSFR promoter was antagonized by GATA-1 in the context of a low level of PU.1 but overcome by a high level of PU.1 (Fig. 4D) . In addition, a positive interaction between PU.1 and GATA-1 was also obtained in transactivation experiments performed in the K562 erythroleukemia cell line that expresses high levels of endogenous GATA-1, such that low levels of the PU.1 expression vector doubled MBP-P2 promoter activity due to endogenous GATA-1, whereas high levels of PU.1 had no effect (Fig. 5) . These findings suggest that the level of PU.1 expression is critical in determining whether GATA-1 and PU.1 functionally antagonize or synergize in the regulation of PU.1 versus GATA-1 target genes in the myeloid lineages.
C/EBP⑀ 27 Represses GATA-1 Transactivation and Blocks GATA-1/PU.1 Synergy in the Activation of the MBP-P2 Promoter-We have shown that all four C/EBP⑀ isoforms are expressed by AML14.3D10 eosinophilic myelocytes (Fig. 2) and that C/EBP⑀ in nuclear extracts of these cells binds the C/EBP consensus site of the MBP-P2 promoter (Fig. 3C ). As well, we reported previously (9) that C/EBP␤ functionally synergizes with and physically interacts with GATA-1. We therefore sought to characterize the functional activities of the different C/EBP⑀ isoforms in terms of both direct transactivating activity and combinatorial effects with GATA-1 and PU.1. Transactivation experiments were carried out in CV-1 cells by cotransfection of the bp Ϫ117-MBP-P2 promoter construct with expression vectors for C/EBP⑀ 32 , C/EBP⑀ 27 , and C/EBP⑀ 14 , and/or GATA-1, and/or PU.1 as shown in Fig. 6 . The MBP-P2 promoter was transactivated by GATA-1 alone but not by any of the individual C/EBP⑀ isoforms (Fig. 6, A and B) . In contrast, GATA-1-induced transactivation was significantly inhibited by the addition of C/EBP⑀ 27 but not by the C/EBP⑀ 32 or C/EBP⑀ 14 isoforms (Fig. 6A) . Furthermore, the synergistic activity of GATA-1 and PU.1 (ϳ75-fold induction) was completely suppressed by the addition of the C/EBP⑀ 27 isoform, but not by the other C/EBP⑀ isoforms (Fig. 6B) . Importantly, the repressor activity of the C/EBP⑀ 27 isoform was not unique to the individual or combinatorial activities of GATA-1 and GATA-1/PU.1 on MBP-P2 promoter activity, as PU.1-mediated transactivation of the M-CSFR promoter was likewise blocked by C/EBP⑀ 27 in these experiments (Fig. 6C) . In addition, the C/EBP⑀ 27 isoform completely blocked PU.1 synergy with endogenous GATA-1 in the K562 cell line in which the MBP-P2 promoter is active (Fig.  6D) . The C/EBP⑀ 27 isoform contains both transactivation and putative repression domains (40, 61, 63) . Its negative regulatory activity in our system may be mediated by the repression domain through either binding to the MBP promoter C/EBP site directly or by protein-protein interactions that interfere with GATA-1 DNA binding, transcriptional activity, or the physical interactions of GATA-1 with PU.1.
We showed previously that the synergistic interactions of GATA-1 and C/EBP␤ likely occur through protein/protein interaction in that they required either a functional GATA-or C/EBP-binding site but not both (9) . As well, GATA-1 and PU.1 have been shown to antagonize functionally one another's functions via protein/protein interactions, whether the target genes
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contain GATA-1-or PU.1-binding sites (11, 84) . Because GATA-1, PU.1, and C/EBP⑀ can all bind to their respective sites in the MBP-P2 promoter (Fig. 3) , we sought to determine the functional relevance of these binding sites in the combinatorial interactions of these transcription factors on this eosinophil promoter. Constructs containing mutations in the dual GATA site, the two C/EBP sites, or both PU.1 sites were generated by PCR mutagenesis using the wild type MBP-P2 promoter construct as template and tested in both CV-1 cells (Fig. 7A) and the AML14 eosinophil cell lines (Fig. 7B) . Transactivation analyses were performed in CV-1 cells as described above by cotransfection of the MBP-P2 mutant and wild type constructs with GATA-1, PU.1, and C/EBP⑀ 27 expression vectors (Fig. 7A) . Activity of the MBP-P2 promoter was essentially eliminated by the mutation of the C/EBP sites or the GATA sites, indicating a requirement for both sites in this promoter. No GATA-1-induced transactivation or GATA-1/PU.1 synergistic transactivation was seen for either the C/EBP or GATA site mutants. In contrast, mutation of the two PU.1 sites in the MBP-P2 promoter was essentially without effect, and both GATA-1-induced transactivation and GATA-1/PU.1 synergy was equivalent to that obtained for the wild type promoter. To confirm this finding for the endogenously expressed factors in eosinophils, the same MBP-P2 promoter wild type and mutant constructs were transiently transfected by electroporation into the AML14.3D10 eosinophil and AML14 parental cell lines (Fig.  7B) . The results confirmed that mutation of the PU.1-binding sites was essentially without effect on MBP-P2 promoter activity compared with the wild type promoter in both cell lines, whereas mutation of either the GATA sites or C/EBP sites resulted in a significant loss of activity. We conclude from these analyses that the synergistic activity of PU.1 on GATA-1-mediated transactivation occurs independently of direct PU.1 binding to either of the two PU.1-binding sites in the MBP-P2 promoter. These results imply that the synergy of PU.1 and GATA-1 in this system is mediated via protein/protein interactions between these factors and binding of the complex through the dual GATA-binding site in the promoter. These results also confirm our prior findings that the C/EBP and GATA sites are both critical for transcriptional activation of this promoter by transactivation in either heterologous cell lines or by the endogenous factors in eosinophil progenitor lines (8, 9) . 1 g) , and the C/EBP⑀ 27 expression vector as indicated, along with the pRL-CMV (Renilla luciferase) control vector. Mean (Ϯ S.D.) promoter activity is expressed as the fold activity relative to the promoterless pXP2 luciferase control vector. Luciferase activity was determined 6 h after transfection and normalized using the dual luciferase method.
Endogenous GATA-1, PU.1, and C/EBP⑀ Isoforms Expressed by Eosinophils Physically Interact; Analysis by Co-immunoprecipitation-
To evaluate further the physical interactions that may occur among GATA-1, PU.1. and C/EBP⑀ in vivo in the eosinophil lineage, we performed co-IP experiments using whole cell lysates of the AML14.3D10 eosinophil myelocyte cell line that expresses all three transcription factors. Whole cell lysates were first immunoprecipitated with antibodies to C/EBP⑀, GATA-1, or PU.1 and two control antibodies including non-immune rabbit and goat IgGs. Immunoprecipitates were analyzed by Western blotting using antibodies against C/EBP⑀ and GATA-1 as shown in Fig. 8 . As shown on the C/EBP⑀ Western blot (Fig. 8A) , antibody to C/EBP⑀ strongly immunoprecipitated both the C/EBP⑀ 32/30 and C/EBP⑀ 27 isoforms (lane 2). Antibodies to PU.1 and GATA-1 both co-immunoprecipitated the C/EBP⑀ 32/30 and C/EBP⑀ 27 isoforms (Fig. 8A, lanes 3  and 5) but not the C/EBP⑀ 14 isoform (not shown). As shown on the GATA-1 Western blot (Fig. 8B) , GATA-1 was efficiently immunoprecipitated by antibody to GATA-1 (lane 5), and antibodies to C/EBP⑀ and PU.1 both co-immunoprecipitated GATA-1 (lanes 2 and 3, respectively) . We were unable to coimmunoprecipitate PU.1 with antibodies to either C/EBP⑀ or GATA-1 (data not shown); the low level expression of endogenous PU.1 in AML14.3D10 cells likely precludes its visualization in these co-immunoprecipitates. Alternatively, antibodies to GATA-1 and C/EBP⑀ may block their interactions with PU.1. Our co-immunoprecipitation results demonstrate for the first time that C/EBP⑀ physically interacts with both PU.1 and GATA-1 in vivo. Our results indicate that C/EBP⑀, GATA-1. and PU.1 physically interact with one another in vivo in AML14.3D10 eosinophil myelocytes. (4, 52) have shown that granulopoiesis is impaired in C/EBP␣-or C/EBP⑀-deficient mice. C/EBP␣ has been shown to play a critical role in early aspects of myeloid lineage commitment and gene transcription, whereas C/EBP⑀ has been shown to be critical for the more terminal stages of lineage differentiation and maturation (4, 40) . To define further the transcriptional regulation of the MBP gene during the various stages of eosinophil development by the members of the C/EBP family, we sought to characterize their combinatorial interactions in the activation of the MBP promoter. Co-transactivation analyses were performed in CV-1 cells by co-transfection of the MBP-P2 promoter construct with expression vectors for C/EBP␣, C/EBP␤, and the three C/EBP⑀ isoforms (⑀ 32 , ⑀ 27 , and ⑀ 14 ). C/EBP␣ or C/EBP␤ equivalently transactivated the MBP-P2 promoter with 4 -8-fold inductions, and these activities were competitively inhibited by the addition of the C/EBP⑀ 14 , C/EBP⑀ 27 , and C/EBP⑀ 32 isoforms as shown in Fig. 9, A and B, respectively. The C/EBP⑀ 14 isoform in FIG. 7 . Activity of the MBP-P2 promoter is eliminated by mutation of the GATA or C/EBP sites but not the PU.1 sites; analysis by transactivation in CV-1 cells and transfection of AML14.3D10 eosinophilic myelocytes. A, CV-1 cells were transfected with 0.5 g of the MBP-P2 wild type or mutant constructs including a dual C/EBP site mutation, dual GATA-1 site mutation, or dual PU.1 site mutation as indicated and shown schematically in Fig. 2 . Transactivation experiments were performed with or without the addition of 0.2 g of GATA-1, 0.01 g of PU.1, or 0.5 g of C/EBP⑀ 27 expression vectors as indicated. Promoter activity is shown as fold induction over the base-line MBP-P2-pXP2 construct alone. Transactivation of the MBP-P2 promoter by GATA-1 or GATA-1/PU.1 synergy and its repression by C/EBP⑀ 27 was blocked by mutation of the C/EBP or GATA-binding sites but not the PU.1 sites. B, AML14 and AML14.3D10 cells were transiently transfected by electroporation using 10 g of promoter constructs including the MBP-P2 wild type or dual GATA-site, C/EBP site, or PU.1 site mutation constructs as above. Luciferase activity was measured 6 h after transfection, normalized, and analyzed as fold differences compared with the promoterless pXP2 luciferase plasmid. The mean (Ϯ S.D.) for three independent transactivation or transfection experiments is shown. 27 particular, which has no transactivating activity in this system (Fig. 6) , inhibited both C/EBP␣-and C/EBP␤-induced transactivation in a dose-dependent manner, possibly by forming inactive heterodimers with these C/EBPs through their shared leucine zipper dimerization domains. The C/EBP⑀ 32 and C/EBP⑀ 27 isoforms, which likewise have no inherent transactivating activity of their own for the MBP-P2 promoter (Fig. 6.) , may also form inactive heterodimers or homodimers that compete for occupation of the functional C/EBP site in the MBP-P2 promoter, decreasing transactivation by C/EBP␣ or -␤.
Activation Versus Repression of Eosinophil Gene Transcription by C/EBP Family Members-Previous studies
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Targeted Disruption of the C/EBP⑀ Gene Results in Only a Partial Decrease in MBP Gene
Expression-Mice with a targeted disruption of the C/EBP⑀ gene fail to produce normal mature granulocytes in their bone marrow or peripheral blood, but they instead produce neutrophils that have atypical nuclear morphology, lack expression of secondary and tertiary granule proteins, and have functional abnormalities. As well, mature eosinophils are not detectable in these mice using standard histochemical staining with Wrights'-Giemsa (4). By comparison, mice with a targeted disruption of the C/EBP␣ gene have a profound absence of both neutrophils and eosinophils in the fetal liver (52) . In C/EBP␣ null mice, we were unable to detect any expression of MBP whatsoever, consistent with a complete block in granulocyte development (Fig. 10 ). In addition, there was no expression of the gene encoding murine eosinophil peroxidase and decreased expression of the gene encoding the IL-5R␣ subunit (not shown). 3 In contrast, in the C/EBP⑀ null mice, there was only a partial (ϳ50%) decrease in MBP mRNA expression (Fig. 10) , with only a partial decrease in murine eosinophil peroxidase, and no effect whatsoever on IL-5R␣ subunit expression (not shown). Thus, although C/EBP⑀ knockout mice do not produce any terminally differentiated mature eosinophils, they must still produce eosinophil progenitors capable of expressing secondary granule protein genes such as MBP and eosinophil peroxidase, albeit at somewhat reduced levels.
DISCUSSION
Basal hematopoiesis is now thought to be regulated in part by combinatorial networks of transcription factors that serve to coordinate the expression of lineage-specific genes at appropriate stages of lineage commitment, proliferation, terminal differentiation, and functional maturation (85, 86) . Thus far, GATA-1, PU.1, and members of the C/EBP family (C/EBP␣ and C/EBP⑀) of transcriptional regulators have been found to play key roles in the commitment and terminal differentiation of myeloid progenitors to the eosinophil lineage in the avian system (1-7) and the regulation of eosinophil lineage-specific gene expression (8, 9) and development (4, 39, 52) in mammals. A physical interaction and functional antagonism between GATA-1 and PU.1 was identified recently by several groups (10 -12) and was shown to play a role in the counter-regulation of myeloid versus erythroid development and transcriptional regulation of myeloid versus erythroid target genes. Moreover, the level of PU.1 expression was found to be a determinant for specifying lymphoid (B cell) versus macrophage lineage development, suggesting that graded expression of PU.1 may play a role in specifying distinct cell fates in hematopoiesis (37) . However, a PU.1/GATA-1 functional antagonism appears inconsistent with the reported roles of these factors in the eosinophil granulocyte lineage. PU.1 is expressed throughout myeloid (87, 88) and eosinophil development and is induced by IL-5 in CD34ϩ hematopoietic progenitors. 4 As well, PU.1 null mice lack detectable eosinophils or expression of eosinophil secondary granule protein genes such as MBP and eosinophil peroxidase, 2 and PU.1 may regulate eosinophil expression of two additional secondary granule ribonuclease genes, eosinophilderived neurotoxin (EDN and RNS2) and eosinophil cationic protein (ECP and RNS3), through a PU.1-binding site in their highly conserved intronic enhancer (6) . As well, GATA-1 has been shown to drive both eosinophil development (3, 7) and eosinophil gene transcription (2, 6, 8, 9) .
In the present work, we have characterized a novel synergistic (as opposed to antagonistic) role for PU.1 in amplifying GATA-1-mediated gene transcription in the eosinophil lineage, an effect that is dependent on the level of PU.1 expression relative to GATA-1, and independent of PU.1 DNA-binding sites in the target promoter. Our findings support the concept that the ratio of GATA-1 to PU.1 may be one of the critical determinants in specifying the eosinophil developmental program compared with neutrophils or other myeloid lineages. Our finding of a PU.1/GATA-1 synergy, rather than antagonism, for a GATA-1-regulated target gene in the eosinophil lineage is in contrast to those reported by others (10, 84) in which PU.1 has been shown to suppress erythroid development and the expression of GATA-1-regulated erythroid genes by blocking GATA-1 binding to DNA. In the opposite direction, GATA-1 has been shown to antagonize PU.1 functions in myeloid gene expression and development when expressed ectopically in human and avian myeloid cells (11, 12) . The effects of GATA-1 on PU.1 function in the myeloid lineage were found to be mediated via a direct interaction of the C-terminal zinc finger of GATA-1 with the PU.1 ets DNA-binding domain (12) , in part by interfering with the binding of PU.1 co-activators such as c-Jun (11) . In granulocyte development in the avian system, the expression of an "intermediate level" of GATA-1 in the context of PU.1 and C/EBP␤ was found to be pivotal to the commitment of multipotential Myb-ets-transformed myeloid progenitors to the eosinophil lineage (3, 89) . As such, antagonism of GATA-1 function by PU.1 in the eosinophil lineage would be at odds with the key role of GATA-1 function in specifying eosinophil versus neutrophil development (7, 12) , and would be expected to block expression of GATA-1-regulated eosinophil genes such as MBP. In the avian system, GATA-1 was found to function as either a transcriptional activator of the EOS47 gene at low levels of expression or repressor at high levels of expression (2, our findings of a GATA-1/PU.1 synergy might be that PU.1 simply "titrates" the optimal level at which GATA-1 activates the MBP-P2 promoter, rather than cooperating directly with GATA-1. To eliminate this as a possibility, we first performed dose-response titrations of the GATA-1 expression vector and selected a concentration for co-transactivation experiments that provided maximum (peak) GATA-1-mediated transactivation (data not shown). In these experiments, GATA-1 functioned exclusively as a transcriptional activator in a dosedependent fashion, with no repressor activity evident. The failure of high concentrations of PU.1 to synergize with GATA-1 in our studies is likely due to its interaction with and reduction of the available GATA-1 in the system. Although our finding that PU.1 synergizes with GATA-1 for transactivation of the eosinophil MBP gene could be a promoter-specific effect (see below), such synergy may be key to the activation and fulfillment of the hematopoietic program of the eosinophil. The synergistic effect of PU.1 on GATA-1-mediated transactivation could potentially be mediated by a conformational change in GATA-1 when it binds to the two tandem GATA sites present in the MBP-P2 promoter. It was reported recently that the ability of GATA-1 to mediate transactivation can be modified by its DNA binding target sequences, such that high affinity tandem and/or palindromic GATA-binding sites found in several different genes including the ⑀-globin silencer (90) and testis GATA-1 promoter of rats and mice (91) may either promote or interfere with GATA-1 transactivating activity (90, 92) . Only the C-terminal zinc finger of GATA-1 is capable of independently binding to a GATA consensus site and stimulating transcription, whereas the N-terminal finger shows no independent DNA binding activity but can modify binding specificity (stabilize or disrupt binding) at some naturally occurring dual GATA sites that have been shown to be critical for gene expression (93) (94) (95) (96) (97) . The dual GATA sites in the MBP P2 promoter are canonical non-overlapping tandem GATA-binding repeats (6 nucleotides apart; Fig. 1 ) that could potentially interact with both the N-and C-terminal zinc fingers of GATA-1. Involvement of the N-terminal zinc finger by binding to the other GATA site in the MBP P2 promoter might trigger a conformational change leading to decreased DNA binding activity of the C-terminal zinc finger and a decrease in transactivating activity, as recently demonstrated by Trainor and colleagues (90) for the ⑀-globin silencer. In our system, a low amount of PU.1 may interact differentially or preferentially with the N-terminal zinc finger of GATA-1 and prevent this decrease in transactivating potential; this would be observed as PU.1/GATA-1 synergy for transactivation of the MBP-P2 promoter. In contrast, expression of a high amount of PU.1 could lead to interactions with both zinc fingers, thus interfering with the DNA binding activity of GATA-1 and abrogating the synergy obtained in our co-transactivation experiments. Of note, PU.1 has been shown to interact with both the C-and N-terminal zinc fingers of GATA-1 (10) . Studies of the specific mechanism leading to GATA-1/PU.1 synergy for eosinophil MBP gene transcription are currently in progress.
C/EBP␣, an essential regulator of hepatocyte and adipocyte differentiation (49, 50), has been found to play a significant role The GAPDH gene was used as a control for semi-quantitation of the mRNA (cDNA) sample input. The mRNA was prepared from the fetal liver (for C/EBP␣) or bone marrow (for C/EBP⑀) of wild-type (ϩ/ϩ), heterozygote (ϩ/Ϫ), and knockout mice (Ϫ/Ϫ), respectively. For the wild-type and C/EBP⑀ knockout analysis (right panels), mice were first stimulated intraperitoneal with thioglycolate broth for 4.5 or 24 h prior to harvesting bone marrow cells as described previously (4) for the preparation of RNA.
in the early commitment of hematopoietic progenitors to myelopoiesis. C/EBP␣-deficient (null) mice show a selective block in the differentiation of granulocytes (both neutrophils and eosinophils) beyond the myeloblast stage (52) and fail to express G-CSF (52) or IL-6 receptors (98). In contrast, C/EBP⑀ acts downstream of C/EBP␣; its expression is limited principally to the myeloid lineage, and it is required for the terminal differentiation and maturation steps of granulopoiesis (40, 57, 99) . Targeted disruption of the C/EBP⑀ gene results in a failure of terminal granulopoiesis, such that C/EBP⑀ null mice lack normal functionally mature neutrophils, have essentially no identifiable eosinophils by standard histochemical staining with eosin-containing dyes, and show a loss of neutrophil (4) or decreased expression of eosinophil (Fig. 10 ) secondary granule protein genes such as MBP. Unlike other C/EBPs, differential promoter utilization and alternative splicing of the human C/EBP⑀ gene results in the generation and expression of four distinct protein isoforms (32, 30, 27 , and 14 kDa) that may play functionally distinct roles during myelopoiesis. In marked contrast, the murine gene encodes only a single full-length 34-kDa isoform translated from a single 1.3-kb mRNA (100) . Although a recent study (101) reports that the murine C/EBP⑀ may function as an activator or repressor in vitro, there are no murine equivalents of the human 27-and 14-kDa C/EBP⑀ isoforms (57) we have identified as possible repressors (Fig. 11) , suggesting important differences in C/EBP⑀-mediated gene transcription in human versus murine granulopoiesis.
In the present study, we have identified novel repressor roles for both the 27-and 14-kDa human C/EBP⑀ isoforms. The C/EBP⑀ 27-kDa isoform, which contains a repressor domain with the KEEXXXPE motif identified in the RD-1⑀ region of rat C/EBP⑀ (101) and rat, human, and chicken C/EBP␤ (101), was found to antagonize both GATA-1 transactivation and GATA-1/PU.1 synergistic activation of the eosinophil MBP-P2 promoter, as well as PU.1-mediated transactivation of PU.1 target genes/promoters such as the M-CSFR, suggesting a potent repressor function for this isoform in myeloid development. The KEEXXXPE motif of rat C/EBP⑀ is required for both its repressor function and protein/protein interactions, as it is for the Sp3 factor (102) , and this motif is also present in the RD-1 of C/EBP␤ (103) and the inhibitory domain (ID-1) of c-Fos and FosB (104) . In contrast, the 14-kDa isoform of C/EBP⑀ does not contain this repressor domain but binds DNA and was found to function effectively as a dominant negative competitor of C/EBP␣-and C/EBP␤-mediated gene transcription. Thus, two of the human C/EBP⑀ isoforms have the capacity to act as negative regulators of myeloid gene expression. Of interest, the lack of transactivating activity by any of the C/EBP⑀ isoforms for the MBP-P2 promoter is in agreement with the essential inactivity of the C/EBP⑀ 32 isoform relative to other C/EBP family members for another eosinophil secondary granule protein gene, the eosinophil-derived neurotoxin (EDN, RNS2) promoter (105) .
As shown by Western blotting, only the C/EBP⑀ 14 isoform is expressed by mature blood eosinophils (at very high levels). Genes encoding MBP and other secondary granule proteins such as eosinophil peroxidase are down-regulated and ultimately silenced as eosinophils terminally differentiate and mature (106) . These findings are consistent with a negative regulatory role for the C/EBP⑀ 14 isoform in eosinophil terminal differentiation, because it lacks a transactivation or repressor (8) and eosinophil development (7), binds to the dual GATA site in the context of C/EBP␣ and/or -␤, to up-regulate activity of this eosinophil lineage-specific promoter (8) . This involves a physical, synergistic interaction between GATA-1 and the C/EBPs (9) . C, PU.1 and GATA-1, through a direct protein-protein interaction that alters GATA-1 conformation and/or binding to increase its activity, synergize to strongly up-regulate transcription of eosinophil lineagespecific genes such as MBP in developing eosinophil progenitors. This does not require the binding of PU.1 to its binding site in the promoter. D, C/EBP⑀ 27 binds to the C/EBP site competing with C/EBP␣ and/or -␤ or heterodimerizes with these C/EBPs and acts as a repressor to down-regulate or turn off MBP gene transcription fully. This occurs either by blocking C/EBP␣ and/or C/EBP␤ function or by inhibiting GATA-1 and GATA-1/PU.1 synergistic transactivation through direct protein/protein interactions during the terminal differentiation stages of eosinophil development. E, of the C/EBP⑀ isoforms, only C/EBP⑀ 14 continues to be expressed in mature blood eosinophils at high levels. This isoform binds to the critical C/EBP site and effectively blocks MBP gene transcription. As well, the lack of GATA-1 and PU.1 expression in the mature blood eosinophil helps to maintain the silence of this gene. 27 domain and may act as a dominant negative regulator either by occupying the C/EBP sites in the promoters of eosinophil secondary granule protein genes, such as MBP, or by heterodimerizing with other C/EBPs (i.e. C/EBP␣ or -␤), forming a functionally inactive dimer. The C/EBP⑀ 27 isoform, which contains both transactivation and repression domains as described above, may also act as a repressor in this process to decrease MBP gene transcription until the expression of other key regulators such as GATA-1 has ceased in the mature eosinophil (Fig. 11) .
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C/EBP␣, which has been shown to play a pivotal role during the early stages of myeloid lineage-specific gene expression and development including regulation of the G-CSF receptor (52) , and eosinophil genes such as the IL-5R␣ subunit 5 (39) , likely functions as a positive regulator for initial transcription of MBP and other eosinophil lineage-specific genes. Our current results suggest that this initial regulation is subsequently amplified through the potent functional interactions among C/EBPs (␣ and ␤), GATA-1, and PU.1 in the eosinophil lineage as modeled in Fig. 11 . In the earliest stages of eosinophil lineage commitment and development, C/EBP␣ and possibly C/EBP␤ serve initially to activate eosinophil (e.g. MBP) gene transcription. As eosinophil differentiation progresses, GATA-1 binds and synergizes with the C/EBPs to strongly up-regulate eosinophil gene transcription, because both C/EBP␤ (9) and C/EBP␣ 6 physically interact and functionally synergize with GATA-1 to activate the MBP-P2 promoter. PU.1, a central transcriptional regulator of the myeloid lineages (1, 27, 107) , which is expressed continually at varying levels during myelopoiesis, may serve to either up-regulate or down-regulate eosinophil gene transcription through synergistic or antagonistic interactions with GATA-1, dependent upon its expression level relative to GATA-1 (3, 12) . During the final stages of eosinophil maturation, expression of GATA-1, PU.1, and all of the C/EBP⑀ isoforms, save for C/EBP⑀ 14 , are significantly reduced (PU.1) or completely absent (GATA-1), resulting in the loss of eosinophil gene activation and potent repression by the dominant negative actions of the C/EBP⑀ 14 isoform (Fig. 11) . This model provides a framework for in vitro and in vivo studies aimed at defining the functional versatility and roles of the various C/EBP⑀ isoforms in terms of their specific interactions with GATA-1 and PU.1, and other C/EBP family members, both in human eosinophil development and myeloid differentiation in general. Studies are in progress using chromatin immunoprecipitation and DNase I in vivo footprinting to characterize eosinophil promoter activity and occupancy in vivo for C/EBP␣, C/EBP␤, the various C/EBP⑀ isoforms, as well as GATA-1 and PU.1 during the different stages of eosinophil lineage commitment, differentiation, and terminal maturation of authentic bone marrow-derived myeloid progenitors.
